Rituximab in Combination With Outpatient Therapy for CD20+ Lymphoma

Sponsor: Bayside Health
Study ID: NCT00280878
Phase: PHASE2
Status: Completed

Conditions

Non-Hodgkin's Lymphoma (CD20+)

Eligibility Criteria

Sex: ALL
Age: 18 Years - N/A
Healthy Volunteers: Not accepted

Interventions

gemcitabine — DRUG
vinorelbine — DRUG
ifosfamide — DRUG
rituximab — DRUG

Study Details

This is a Phase II pilot study evaluating the safety of a risk-adjusted outpatient-based approach to lymphoma salvage therapy with VGF (vinorelbine, gemcitabine and pegfilgrastim) and/or F-GIV (gemcitabine, Ifosfamide, vinorelbine and pegfilgrastim) in combination with Rituximab (R-VGF/R-F-GIV).

Key Dates

Start date: Jan 31, 2006
Status verified: Oct 2007
Completion: Sep 30, 2007

Study Design

Enrollment: 12 participants (estimated)
Allocation: NON_RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: TREATMENT

Primary Outcome Measure

To evaluate the safety of a risk-adjusted outpatient-based approach to lymphoma salvage therapy with VGF and/or F-GIV in combination with Rituximab.